Business
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDS...
About this update from Telo Genomics Corp.
[{"type":"text","content":"European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 CongressToronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association (\"EHA\") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming EHA 2025 Congress.The new abstract is titled \"Advanced Risk Prediction for Smoldering Multiple Myeloma (\"SMM\") Patients Through the Combination of Mayo Clinic's 2/20/20 Model with TeloViewSMM Risk Assessment.\" It reports a synergistic outcome from the co-application of the 2 assessments, for determining the risk of progression from SMM to active multiple myeloma. For the 88 patients examined, the predictive accuracies corresponding to Receiver Operating Characteristic (\"ROC\") curves were 0.64 for 2/20/20, 0.77 for TeloViewSMM and 0.80 when applied together.The abstract will be presented on June 14th by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic, Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies. Dr. Kumar has played a pivotal role in developing the 2/20/20 risk stratification model, which is currently included in the smoldering myeloma prognostic international guidelines.\"We are pleased to be presenting our abstract at EHA. The 2/20/20 risk model has found broad implementation in the clinic, and it has been further refined by inclusion of cytogenetic abnormalities with fluorescence in situ hybridization (FISH) testing,\" said Dr. Sabine Mai, Telo's Co-Founder. \"Since TeloViewSMM could also be added to existing FISH laboratory workflows, the co-use of these assessments is now appearing both highly scalable and clinically advantageous.\"About TeloView-SMMThe TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients.High ri...